Krebs Biochemicals & Industries Limited (KREBSBIO.NS)
NSE · INR · Healthcare · Drug Manufacturers - Specialty & Generic
₹59.64 (-4.15%) as of
Key statistics
- Market cap
- 1.29B
- EPS (TTM)
- -6.54
- Dividend yield
- 0.00%
- 52-week range
- 38.33 – 76.85
- Beta
- 0.90
- Revenue (TTM)
- 252.34M
- Profit margin
- -55.85%
- Volume
- 102.28k
About Krebs Biochemicals & Industries Limited
Krebs Biochemicals & Industries Limited engages in the manufacture of active pharmaceutical ingredients in India. It offers androstenedione for steroid intermediate indications, as well as lovastatin and simvastatin for anti-cholesterol applications. The company also develops amlodipine and telmisartan for anti-hypertension; cetirizine for antihistamine; orlistat for anti-obesity; serratiopeptidase for anti-inflammatory; and phenylephrine for cold and cough. In addition, it provides contract manufacturing services for large pharmaceutical and multinational companies. The company was incorporated in 1991 and is based in Visakhapatnam, India.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Visakhapatnam, India
- Employees
- 142
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.